Clinical mass spectrometry · Olomouc

Mass spectrometry,
translated to the clinic.

We develop and apply LC-MS/MS, metabolomics and lipidomics workflows to understand disease mechanisms, discover clinically relevant biomarkers and support the translation of omics technologies into laboratory medicine.

LC-MS/MS · high-resolution Acquiring
Scan
482.61 m/z
Polarity
ESI−
Range
100–1000
A joint group of University Hospital Olomouc & Palacký University
Palacký University OlomoucUniversity Hospital Olomouc
0
Publications in record
0
Researchers & students
0
Clinical focus areas
0
Years of published research

What we do

Mass spectrometry workflows for clinically meaningful omics research

We combine clinical laboratory expertise with targeted mass spectrometry, metabolomics and lipidomics to study disease mechanisms and develop clinically meaningful analytical workflows.

01 / 04

Clinical LC-MS/MS

Development and validation of targeted LC-MS/MS methods for laboratory medicine — small molecules, steroids, organic acids and biomarkers of inherited metabolic disorders.

02 / 04

Metabolomics

Targeted metabolomic workflows for the investigation of human disease, biochemical phenotyping and translational biomarker discovery.

03 / 04

Lipidomics

Quantitative lipidomics focused on inflammation, infection, cardiovascular risk and disease-associated remodelling of lipid pathways.

04 / 04

Multi-omics & data analysis

Integration of metabolomics, lipidomics, proteomics and clinical data using robust statistics, visualisation and biomarker modelling.

Clinical questions

Where mass spectrometry meets clinical questions

We apply mass spectrometry-based omics to clinically relevant questions where lipid and metabolite profiles may improve disease understanding, patient stratification or laboratory diagnostics.

01

Inflammation and infection

Distinguishing infectious and sterile inflammation using lipid and metabolite signatures in clinically relevant matrices.

02

Inherited metabolic disorders

LC-MS/MS workflows for selective screening, diagnostics and biochemical characterisation of inborn errors of metabolism.

03

Cardiovascular risk lipidomics

Lipid-based risk stratification with a focus on ceramides, phospholipids and disease-associated lipid remodelling.

04

Immune-mediated diseases

Multi-omics profiling of inflammatory bowel disease and immune-mediated conditions using metabolomics, lipidomics and proteomics.

05

Perioperative and stress metabolism

Metabolic and lipidomic changes associated with surgery, stress response and clinical recovery.

From spectra to insight

From raw spectra
to clinical insight.

Every measurement is also a data problem. We build reproducible pipelines that turn complex LC-MS/MS output into interpretable, clinically useful information.

  • 01 Targeted method development and validation
  • 02 Reproducible processing in R and Python
  • 03 Robust statistics and biomarker modelling
  • 04 Visualisation built for clinical interpretation
TIC chromatogram LC-MS/MS
Retention time → intensity
Lipid classes mol %
Relative abundance
PCA of lipidome n = 148
Controls Patients
Longitudinal profiles 12 months
Schematic visualisations · illustrative data

Collaborate with us

Join the group or start a collaboration.

We are open to motivated students, PhD candidates and clinical or research partners interested in translational omics, lipidomics, metabolomics and clinical LC-MS/MS.